Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1645
This examiner grants 53% of resolved cases
Jana A. Hines is an examiner in Tech Center 1600 and Art Unit 1645, with 707 resolved cases. Her allowance rate of 53.0% indicates a moderate level of difficulty for applicants. The median days to allowance is 1243, which provides a clear expectation for the duration of the prosecution process. These metrics, based on 707 resolved cases, offer a solid foundation for understanding her examination patterns.
The interview lift pct of 39.7% is a significant finding, suggesting that interviews are highly effective at increasing the chances of a grant. This lift can move the 53.0% allowance rate into a much more favorable range. Given the 1243 median days to allowance, practitioners should prioritize interviews as a way to resolve disagreements and potentially shorten the time to allowance. The large number of 707 resolved cases ensures that these statistics are a reliable guide for practice in Art Unit 1645.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 16157885 | METHODS AND SYSTEMS, FOR INTERFERING WITH VIABILITY OF BACTERIA AND RELATED ANTIMICROBIALS AND COMPOSITIONS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17279012 | HIGH SPECIFICITY AND SENSITIVITY IMMUNOSORBENT DIAGNOSTIC ASSAYS WITH SIMULTANEOUS RESOLUTION OF MULTIPLE ANTIBODY ISOTYPES | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18459221 | METHODS OF TREATING NON-SMALL CELL LUNG CANCER USING MESENCHYMAL EPITHELIAL TRANSITION FACTOR (MET)-TARGETED AGENTS | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18038519 | METHODS OF PREVENTING, DELAYING OR AMELIORATING ATOPIC DISEASES | Non-Final OA | Johnson & Johnson Consumer Inc. |
| 18272483 | METHOD AND KIT FOR DETECTING PRESENCE AND/OR AMOUNT OF BACTERIA IN FOOD/DRINK SAMPLE, ENVIRONMENTAL SAMPLE, OR BIOLOGICAL SAMPLE | Non-Final OA | ASAHI KASEI KABUSHIKI KAISHA |
| 18640574 | Antigenic OspA Polypeptides | Non-Final OA | SANOFI |
| 17627399 | METHOD FOR DETERMINING THE RISK OF AN AVIAN PATHOGENIC E. COLI (APEC) INFECTION IN AN AVIAN FLOCK | Non-Final OA | EVONIK OPERATIONS GMBH |
| 18386537 | METHODS FOR TREATING NEPHROTIC SYNDROME | Non-Final OA | Cedars-Sinai Medical Center |
| 18425731 | PROBIOTICS TO RESCUE MATERNAL IMMUNE ACTIVATION-INDUCED NEURODEVELOPMENT DEFICITS | Non-Final OA | The University of Chicago |
| 17517084 | TREATMENT OF CANCER BY MANIPULATION OF COMMENSAL MICROFLORA | Final Rejection | The University of Chicago |
| 18259219 | MICROBIAL MICROCAPSULE AND METHOD FOR PRODUCING SAME | Final Rejection | KAO CORPORATION |
| 18469188 | PHARMACEUTICAL COMPOSITION COMPRISING A PROBIOTIC AND PREBIOTIC TO PREVENT ACQUISITION OF OR TREAT DRUG RESISTANT INFECTIONS | Non-Final OA | Chr. Hansen A/S |
| 17520402 | CHIMERIC ANTIGEN RECEPTORS CONTAINING A CHLOROTOXIN DOMAIN | Final Rejection | City of Hope |
| 17063977 | PD1 AND PDL1 ANTIBODIES AND VACCINE COMBINATIONS AND USE OF SAME FOR IMMUNOTHERAPY | Non-Final OA | Inovio Pharmaceuticals, Inc. |
| 18632573 | METHODS AND COMPOSITIONS FOR IMPROVING ENGINEERED MICROBES THAT FIX NITROGEN | Non-Final OA | Pivot Bio, Inc. |
| 18510979 | Therapeutic Microvesicles of Probiotic Bacteria | Non-Final OA | BioGaia AB |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy